Modulating biomechanical and integrating biochemical cues to foster adaptive remodeling of tissue engineered matrices for cardiovascular implants
Source abstract
Abstract
Cardiovascular disease remains one of the leading causes of mortality in the Western world. Congenital heart disease affects nearly 1 % of newborns, with approximately one-fourth requiring reconstructive surgery during their lifetime. Current cardiovascular replacement options have significant limitations. Their inability to grow poses particular challenges for pediatric patients. Tissue Engineered Matrix (TEM)-based in situ constructs, with their self-repair and growth potential, offer a promising solution to overcome the limitations of current clinically used replacement options. Various functionalization strategies, involving the integration of biomechanical or biochemical components to enhance biocompatibility, have been developed for Tissue Engineered Vascular Grafts (TEVG) and Tissue Engineered Heart Valves (TEHV) to foster their capacity for in vivo remodeling. In this review, we present the current state of clinical translation for TEVG and TEHV, and provide a comprehensive overview of biomechanical and biochemical functionalization strategies for TEVG and TEHV. We discuss the rationale for functionalization, the implementation of functionalization cues in TEM-based TEVG and TEHV, and the interrelatedness of biomechanical and biochemical cues in the in vivo response. Finally, we address the challenges associated with functionalization and discuss how interdisciplinary research, especially when combined with in silico models, could enhance the translation of these strategies into clinical applications. STATEMENT OF SIGNIFICANCE: Cardiovascular disease remains one of the leading causes of mortality, with current replacements being unable to grow and regenerate. In this review, we present the current state of clinical translation for tissue engineered vascular grafts (TEVG) and heart valves (TEHV). Particularly, we discuss the rationale and implementation for functionalization cues in tissue engineered matrix-based TEVGs and TEHVs, and for the first time we introduce the interrelatedness of biomechanical and biochemical cues in the in-vivo response. These insights pave the way for next-generation cardiovascular implants that promise better durability, biocompatibility, and growth potential. Finally, we address the challenges associated with functionalization and discuss how interdisciplinary research, especially when combined with in silico models, could enhance the translation of these strategies into clinical applications .
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrospun Nanofibers in Biomedical Applications · Tissue Engineering and Regenerative Medicine · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. 2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association10.1161/CIR.0000000000001209 ↗
2. The early days of vascular and heart valve prostheses: a historical review10.23736/S0021-9509.19.11011-7 ↗
3. Birth prevalence of congenital heart disease worldwide10.1016/j.jacc.2011.08.025 ↗
4. The long-term follow-up of large-diameter Dacron® vascular grafts in surgical practice: a review10.23736/S0021-9509.16.08061-7 ↗
5. Clinical studies of Gore-Tex vascular prostheses. A review of the literature
6. Vascular grafts: technology success/technology failure10.34133/bmef.0003 ↗
7. Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenograftsq
8. Long-term follow-up of patients with synthetic right heart conduits
9. The outcome of antibiotic sterilised aortic homografts used in the Fontan procedure10.1016/1010-7940(93)90067-L ↗
10. Clinical outcome of 193 extracardiac fontan patients10.1016/j.jacc.2005.12.065 ↗
11. Heart valve health, disease, replacement, and repair: a 25-year cardiovascular pathology perspective10.1016/j.carpath.2016.05.002 ↗
12. Tissue engineering: relevance to neonatal congenital heart disease10.1016/j.siny.2021.101225 ↗
13. Patch materials for pulmonary artery arterioplasty and right ventricular outflow tract augmentation: a review10.1007/s00246-023-03152-7 ↗
14. Next-generation tissue-engineered heart valves with repair, remodelling and regeneration capacity10.1038/s41569-020-0422-8 ↗
15. Biomaterial-driven in situ cardiovascular tissue engineering–a multi-disciplinary perspective10.1038/s41536-017-0023-2 ↗
16. A novel restorative pulmonary valve conduit: early outcomes of two clinical trials10.3389/fcvm.2020.583360 ↗
17. In situ heart valve tissue engineering using a bioresorbable elastomeric implant - from material design to 12 months follow-up in sheep10.1016/j.biomaterials.2017.02.007 ↗
18. Total cavopulmonary connection with a new restorative vascular graft: results at 2 years10.21037/jtd-19-739 ↗
19. Spontaneous reversal of stenosis in tissue-engineered vascular grafts10.1126/scitranslmed.aax6919 ↗
20. Decellularized fresh homografts for pulmonary valve replacement: a decade of clinical experience †10.1093/ejcts/ezw050 ↗
21. Allograft heart valves: current aspects and future applications10.1089/bio.2016.0070 ↗
22. Riboflavin-mediated photooxidation to improve the characteristics of decellularized human arterial small diameter vascular grafts10.1016/j.actbio.2020.08.037 ↗
23. Acellular vascular matrix grafts from human placenta chorion: impact of ECM preservation on graft characteristics, protein composition and in vivo performance10.1016/j.biomaterials.2018.05.045 ↗
24. Small intestinal submucosa extracellular matrix (CorMatrix®) in cardiovascular surgery: a systematic review10.1093/icvts/ivw020 ↗
25. Porcine intestinal submucosa (CorMatrix) for semilunar valve repair in children: a word of caution after midterm results10.1053/j.semtcvs.2016.04.015 ↗
26. Bovine carotid artery (Artegraft) as a hemodialysis access conduit in patients who are poor candidates for native arteriovenous fistulae10.1177/1538574414561231 ↗
27. Bovine mesenteric vein graft (ProCol) in critical limb ischaemia with tissue loss and infection10.1016/j.ejvs.2003.12.001 ↗
28. Randomized clinical trial comparing decellularized bovine ureter with expanded polytetrafluoroethylene for vascular access10.1002/bjs.6434 ↗
29. 6-Month aortic valve implantation of an off-the-shelf tissue-engineered valve in sheep10.1016/j.biomaterials.2015.09.016 ↗
30. Pediatric tubular pulmonary heart valve from decellularized engineered tissue tubes10.1016/j.biomaterials.2015.05.009 ↗
31. Implantation of a tissue-engineered tubular heart valve in growing lambs10.1007/s10439-016-1605-7 ↗
32. Pediatric tri-tube valved conduits made from fibroblast-produced extracellular matrix evaluated over 52 weeks in growing lambs10.1126/scitranslmed.abb7225 ↗
33. Off-the-shelf human decellularized tissue-engineered heart valves in a non-human primate model10.1016/j.biomaterials.2013.04.059 ↗
34. Transcatheter implantation of homologous “off-the-shelf” tissue-engineered heart valves with self-repair capacity: long-term functionality and rapid in vivo remodeling in sheep10.1016/j.jacc.2013.09.082 ↗
35. Computational modeling guides tissue-engineered heart valve design for long-term in vivo performance in a translational sheep model10.1126/scitranslmed.aan4587 ↗
36. Development of an off-the-shelf tissue-engineered sinus valve for transcatheter pulmonary valve replacement: a proof-of-concept study10.1007/s12265-018-9800-6 ↗
37. Development of a novel Human cell-derived tissue-engineered heart valve for transcatheter aortic valve replacement: an in vitro and in vivo feasibility study10.1007/s12265-018-9821-1 ↗
38. Human cell-derived tissue-engineered heart valve with integrated Valsalva sinuses: towards native-like transcatheter pulmonary valve replacements10.1038/s41536-019-0077-4 ↗
39. Chapter 9–re-engineered cell-derived extracellular matrix as a new approach to clarify the role of native ECM
40. Emerging strategies for optimizing cell-derived decellularized extracellular matrix scaffolds in tissue engineering
41. Creation of viable pulmonary artery autografts through tissue engineering10.1016/S0022-5223(98)70315-0 ↗
42. Tissue engineered heart valves for transcatheter aortic valve implantation: current state, challenges, and future developments10.1080/14779072.2020.1792777 ↗
43. Immuno-regenerative biomaterials for in situ cardiovascular tissue engineering - do patient characteristics warrant precision engineering?10.1016/j.addr.2021.113960 ↗
44. A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts10.1096/fj.11-186585 ↗
45. Pulmonary arterioplasty with decellularized allogeneic patches10.1016/j.athoracsur.2013.12.005 ↗
46. Decellularized extracellular matrix scaffolds for cardiovascular tissue engineering: current techniques and challenges10.3390/ijms232113040 ↗
47. Decellularized blood vessel development: current state-of-the-art and future directions
48. Progress in biomaterials inspired by the extracellular matrix10.1016/j.giant.2024.100323 ↗
49. Unreliability of depopulated bovine ureteric xenograft for infra inguinal bypass surgery: mid-term results from two vascular centres10.1016/j.ejvs.2006.10.007 ↗
50. An overview of tissue and whole organ decellularization processes10.1016/j.biomaterials.2011.01.057 ↗
51. Histologic examination of decellularized porcine intestinal submucosa extracellular matrix (CorMatrix) in pediatric congenital heart surgery10.1016/j.carpath.2015.08.007 ↗
52. Use of bioengineered human acellular vessels to treat traumatic injuries in the Ukraine–Russia conflict
53. Five year outcomes in patients with end stage renal disease who received a bioengineered human acellular vessel for dialysis access10.1016/j.ejvsvf.2022.01.003 ↗
54. Six-year outcomes of a phase II study of human-tissue engineered blood vessels for peripheral arterial bypass
55. Late-term results of tissue-engineered vascular grafts in humans10.1016/j.jtcvs.2009.09.057 ↗
56. Morphology and mechanisms of a novel absorbable polymeric conduit in the pulmonary circulation of sheep10.1016/j.carpath.2018.10.008 ↗
57. Tissue-engineered vascular grafts in children with congenital heart disease: intermediate term follow-up10.1053/j.semtcvs.2018.02.002 ↗
58. Total cavopulmonary connection with a new bioabsorbable vascular graft: first clinical experience10.1016/j.jtcvs.2016.11.071 ↗
59. Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model10.1097/SLA.0b013e318184dcbd ↗
60. Rational design of an improved tissue-engineered vascular graft: determining the optimal cell dose and incubation time10.2217/rme.15.85 ↗
61. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts10.1016/j.biomaterials.2012.03.015 ↗
62. Humacyte, Inc., A phase 3 study to compare the efficacy and safety of humacyte's human acellular vessel with that of an autologous arteriovenous fistula in subjects with end stage renal disease, clinicaltrials.Gov, 2023. https://clinicaltrials.gov/study/NCT03183245 (accessed January 1, 2024).
63. Functional arteries grown in vitro10.1126/science.284.5413.489 ↗
64. Tubular heart valves from decellularized engineered tissue10.1007/s10439-013-0872-9 ↗
65. 5-Year results from the prospective European multi-centre study on decellularized homografts for pulmonary valve replacement ESPOIR Trial and ESPOIR Registry data10.1093/ejcts/ezac219 ↗
66. Five-year results from a prospective, single-arm European trial on decellularized allografts for aortic valve replacement–The ARISE Study and ARISE registry data10.1093/ejcts/ezae121 ↗
67. Congenital aortic valve repair using CorMatrix®: a histologic evaluation10.1111/xen.12341 ↗
68. 20-Year follow-up and comparison of valved conduits used for right ventricular outflow tract reconstruction: single-centre, propensity score match analysis
69. Long-term results after the Ross procedure with the decellularized AutoTissue Matrix P® bioprosthesis used for pulmonary valve replacement10.1093/ejcts/ezy377 ↗
70. Preliminary experience with porcine intestinal submucosa (CorMatrix) for valve reconstruction in congenital heart disease: histologic evaluation of explanted valves10.1016/j.jtcvs.2014.02.081 ↗
71. Calcific degeneration of CorMatrix 4 years after bicuspidization of unicuspid aortic valve10.1016/j.athoracsur.2017.07.040 ↗
72. Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outflow tract reconstruction in patients with congenital heart disease10.1093/ejcts/ezr221 ↗
73. Formation of multiple conduit aneurysms following Matrix P® conduit implantation in a boy with tetralogy of Fallot and pulmonary atresia10.1093/ejcts/ezt635 ↗
74. Can we grow valves inside the heart? Perspective on material-based in situ heart valve tissue engineering10.3389/fcvm.2018.00054 ↗
75. Differential leaflet remodeling of bone marrow cell pre-seeded versus nonseeded bioresorbable transcatheter pulmonary valve replacements10.1016/j.jacbts.2019.09.008 ↗
76. In situ heart valve tissue engineering using a bioresorbable elastomeric implant–from material design to 12 months follow-up in sheep10.1016/j.biomaterials.2017.02.007 ↗
77. Inflammatory and regenerative processes in bioresorbable synthetic pulmonary valves up to two years in sheep–Spatiotemporal insights augmented by Raman microspectroscopy10.1016/j.actbio.2021.09.005 ↗
78. The innate immune system contributes to tissue-engineered vascular graft performance10.1096/fj.14-268334 ↗
79. G. Garoffolo, M. Pesce, Mechanotransduction in the cardiovascular system: from developmental origins to homeostasis and pathology, Cells 8 (2019). 10.3390/cells8121607.10.3390/cells8121607 ↗
80. Mechanotransduction in cardiovascular morphogenesis and tissue engineering10.1016/j.gde.2019.08.002 ↗
81. Costameres, dense plaques and podosomes: the cell matrix adhesions in cardiovascular mechanosensing10.1007/s10974-019-09529-7 ↗
82. Tenascin-C in development and disease of blood vessels10.1002/ar.22985 ↗
83. Biomechanical signal communication in vascular smooth muscle cells10.1007/s12079-020-00576-1 ↗
84. Cellular mechanotransduction: from tension to function10.3389/fphys.2018.00824 ↗
85. It takes more than two to tango: mechanosignaling of the endothelial surface10.1007/s00424-020-02369-2 ↗
86. Extracellular matrix, mechanotransduction and structural hierarchies in heart tissue engineering10.1098/rstb.2007.2114 ↗
87. Cardiac valve interstitial cells secrete fibronectin and form fibrillar adhesions in response to injury10.1016/j.carpath.2007.02.008 ↗
88. Valvular endothelial cells regulate the phenotype of interstitial cells in co-culture: effects of steady shear stress10.1089/ten.2006.12.905 ↗
89. Unique morphology and focal adhesion development of valvular endothelial cells in static and fluid flow environments10.1161/01.ATV.0000130462.50769.5a ↗
90. Chapter 10 - the cytoskeletal connection to ion channels as a potential mechanosensory mechanism: lessons from polycystin-2 (TRPP2)
91. Ion channels in the development and remodeling of the aortic valve10.3390/ijms24065860 ↗
92. Oscillatory flow modulates mechanosensitive klf2a expression through trpv4 and trpp2 during heart Valve development10.1016/j.cub.2015.03.038 ↗
93. A change of heart: new roles for cilia in cardiac development and disease10.1038/s41569-021-00635-z ↗
94. Caveolae couple mechanical stress to integrin recycling and activation10.7554/eLife.82348 ↗
95. Endothelial glycocalyx dysfunction in disease: albuminuria and increased microvascular permeability10.1002/path.3964 ↗
96. A new constitutive framework for arterial wall mechanics and a comparative study of material models
97. Blood flow in arteries
98. Clinicopathologic correlations, and mechanisms in heart valve health and disease10.1007/s13239-016-0277-7 ↗
99. A functionally graded material model for the transmural stress distribution of the aortic valve leaflet10.1016/j.jbiomech.2017.01.039 ↗
100. Heart valve macro- and microstructure10.1098/rstb.2007.2125 ↗